Magnetic resonance in the era of molecular imaging of cancer.

Magnetic resonance imaging (MRI) has played an important role in the diagnosis and management of cancer since it was first developed, but other modalities also continue to advance and provide complementary information on the status of tumors. In the future, there will be a major continuing role for noninvasive imaging in order to obtain information on the location and extent of cancer, as well as assessments of tissue characteristics that can monitor and predict treatment response and guide patient management. Developments are currently being undertaken that aim to provide improved imaging methods for the detection and evaluation of tumors, for identifying important characteristics of tumors such as the expression levels of cell surface receptors that may dictate what types of therapy will be effective and for evaluating their response to treatments. Molecular imaging techniques based mainly on radionuclide imaging can depict numerous, specific, cellular and molecular markers of disease and have unique potential to address important clinical and research challenges. In this review, we consider what continuing and evolving roles will be played by MRI in this era of molecular imaging. We discuss some of the challenges for MRI of detecting imaging agents that report on molecular events, but highlight also the ability of MRI to assess other features such as cell density, blood flow and metabolism which are not specific hallmarks of cancer but which reflect molecular changes. We discuss the future role of MRI in cancer and describe the use of selected quantitative imaging techniques for characterizing tumors that can be translated to clinical applications, particularly in the context of evaluating novel treatments.

[1]  R. Shulman,et al.  Detection of metabolites in rabbit brain by 13C NMR spectroscopy following administration of [1‐13C]glucose , 1986, Magnetic resonance in medicine.

[2]  Craig H Meyer,et al.  Technology Insight: in vivo cell tracking by use of MRI , 2006, Nature Clinical Practice Cardiovascular Medicine.

[3]  Sarah E Bohndiek,et al.  Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors , 2009, Proceedings of the National Academy of Sciences.

[4]  J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[5]  N. Hylton,et al.  Improved tumor vascular function following high‐dose epidermal growth factor receptor tyrosine kinase inhibitor therapy , 2007, Journal of magnetic resonance imaging : JMRI.

[6]  J. Bankson,et al.  Macromolecular dynamic contrast‐enhanced (DCE)‐MRI detects reduced vascular permeability in a prostate cancer bone metastasis model following anti–platelet‐derived growth factor receptor (PDGFR) therapy, indicating a drop in vascular endothelial growth factor receptor (VEGFR) activation , 2008, Magnetic resonance in medicine.

[7]  L. Hedlund,et al.  MR Imaging with Hyperpolarized 3He Gas , 1995, Magnetic resonance in medicine.

[8]  Martin O Leach,et al.  Therapeutic target metabolism observed using hyperpolarized 15N choline. , 2008, Journal of the American Chemical Society.

[9]  A. Kangarlu,et al.  Ultra high resolution imaging of the human head at 8 tesla: 2K x 2K for Y2K. , 2000, Journal of computer assisted tomography.

[10]  T E Yankeelov,et al.  A theoretical framework to model DSC-MRI data acquired in the presence of contrast agent extravasation , 2009, Physics in medicine and biology.

[11]  Mark D Pagel,et al.  An overview of responsive MRI contrast agents for molecular imaging. , 2008, Frontiers in bioscience : a journal and virtual library.

[12]  M. Bellin,et al.  Currently used non-specific extracellular MR contrast media , 2003, European Radiology.

[13]  Bradford A Moffat,et al.  An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. , 2007, Cancer research.

[14]  A. Rehemtulla,et al.  Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy , 2000, Gene Therapy.

[15]  Jan Wolber,et al.  Diffusion MRI for prediction of response of rectal cancer to chemoradiation , 2002, The Lancet.

[16]  Bradford A Moffat,et al.  Therapeutic Efficacy of DTI-015 using Diffusion Magnetic Resonance Imaging as an Early Surrogate Marker , 2004, Clinical Cancer Research.

[17]  James M Provenzale,et al.  Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. , 2002, Radiology.

[18]  J. Pipe,et al.  Early detection of treatment response by diffusion-weighted 1H-NMR spectroscopy in a murine tumour in vivo. , 1996, British Journal of Cancer.

[19]  Dmitri Artemov,et al.  Molecular magnetic resonance imaging with targeted contrast agents , 2003, Journal of cellular biochemistry.

[20]  J. M. Taylor,et al.  Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. , 2000, Journal of the National Cancer Institute.

[21]  R. Kreis Quantitative localized 1H MR spectroscopy for clinical use , 1997 .

[22]  J. Gore,et al.  A quantitative study of relaxation rate enhancement produced by iron oxide particles in polyacrylamide gels and tissue , 1989, Magnetic resonance in medicine.

[23]  A. Sherry,et al.  A responsive europium(III) chelate that provides a direct readout of pH by MRI. , 2010, Journal of the American Chemical Society.

[24]  Jinyuan Zhou,et al.  Amide proton transfer (APT) contrast for imaging of brain tumors , 2003, Magnetic resonance in medicine.

[25]  Scott W. Atlas,et al.  Magnetic Resonance Imaging of the Brain and Spine , 1991 .

[26]  Aaron M Mohs,et al.  Gadolinium(III)-based blood-pool contrast agents for magnetic resonance imaging: status and clinical potential , 2007, Expert opinion on drug delivery.

[27]  A Radjenovic,et al.  Measurement of pharmacokinetic parameters in histologically graded invasive breast tumours using dynamic contrast-enhanced MRI. , 2008, The British journal of radiology.

[28]  Toshinori Hirai,et al.  Usefulness of diffusion‐weighted MRI with echo‐planar technique in the evaluation of cellularity in gliomas , 1999, Journal of magnetic resonance imaging : JMRI.

[29]  Bradford A Moffat,et al.  Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  H. Kauczor,et al.  Assessment of Irradiated Brain Metastases by Means of Arterial Spin-Labeling and Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MRI: Initial Results , 2004, Investigative radiology.

[31]  Thomas E Yankeelov,et al.  Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology: Theory, Data Acquisition, Analysis, and Examples. , 2007, Current medical imaging reviews.

[32]  Jan Wolber,et al.  Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy , 2007, Nature Medicine.

[33]  A Dean Sherry,et al.  Paramagnetic lanthanide complexes as PARACEST agents for medical imaging. , 2006, Chemical Society reviews.

[34]  Rolf Gruetter,et al.  Localized 13C NMR Spectroscopy in the Human Brain of Amino Acid Labeling from d‐[1‐13C]Glucose , 1994, Journal of neurochemistry.

[35]  D. Collins,et al.  Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. , 2007, AJR. American journal of roentgenology.

[36]  J G Pipe,et al.  In vivo MR determination of water diffusion coefficients and diffusion anisotropy: correlation with structural alteration in gliomas of the cerebral hemispheres. , 1995, AJNR. American journal of neuroradiology.

[37]  Anthony Fyles,et al.  Correlations between dynamic contrast‐enhanced magnetic resonance imaging–derived measures of tumor microvasculature and interstitial fluid pressure in patients with cervical cancer , 2007, Journal of magnetic resonance imaging : JMRI.

[38]  R. Kauppinen,et al.  Monitoring thymidine kinase and ganciclovir-induced changes in rat malignant glioma in vivo by nuclear magnetic resonance imaging. , 1998, Cancer gene therapy.

[39]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[40]  N. Hayashi,et al.  Intravoxel Incoherent Motion (IVIM) MRI in Intracranial, Extraaxial Tumors and Cysts , 1992, Journal of computer assisted tomography.

[41]  Andreas Makris,et al.  Early Changes in Functional Dynamic Magnetic Resonance Imaging Predict for Pathologic Response to Neoadjuvant Chemotherapy in Primary Breast Cancer , 2008, Clinical Cancer Research.

[42]  Peter C M van Zijl,et al.  MRI detection of glycogen in vivo by using chemical exchange saturation transfer imaging (glycoCEST) , 2007, Proceedings of the National Academy of Sciences.

[43]  T L Chenevert,et al.  Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  D. Donoho,et al.  Sparse MRI: The application of compressed sensing for rapid MR imaging , 2007, Magnetic resonance in medicine.

[45]  Risto A Kauppinen,et al.  Monitoring cytotoxic tumour treatment response by diffusion magnetic resonance imaging and proton spectroscopy , 2002, NMR in biomedicine.

[46]  M Hoehn-Berlage,et al.  High resolution quantitative relaxation and diffusion mri of three different experimental brain tumors in rat , 1995, Magnetic resonance in medicine.

[47]  Daniel B Kopans,et al.  Breast cancer: regional blood flow and blood volume measured with magnetic susceptibility-based MR imaging--initial results. , 2002, Radiology.

[48]  J. Gore,et al.  Molecular Imaging Without Radiopharmaceuticals? , 2009, Journal of Nuclear Medicine.

[49]  Robert E Lenkinski,et al.  PARACEST agents: modulating MRI contrast via water proton exchange. , 2003, Accounts of chemical research.

[50]  Ying Lu,et al.  Kinetic assessment of breast tumors using high spatial resolution signal enhancement ratio (SER) imaging , 2007, Magnetic resonance in medicine.

[51]  J. Galons,et al.  MRI‐measured water mobility increases in response to chemotherapy via multiple cell‐death mechanisms , 2007, NMR in biomedicine.

[52]  R. Edelman,et al.  Magnetic resonance imaging (2) , 1993, The New England journal of medicine.

[53]  L. Shen,et al.  Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. , 2008, Radiology.

[54]  R. Gillies,et al.  Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. , 1999, Neoplasia.

[55]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[56]  Ferdia A Gallagher,et al.  A comparison between radiolabeled fluorodeoxyglucose uptake and hyperpolarized (13)C-labeled pyruvate utilization as methods for detecting tumor response to treatment. , 2009, Neoplasia.

[57]  R. Gruetter,et al.  Feasibility of in vivo 15N MRS detection of hyperpolarized 15N labeled choline in rats. , 2010, Physical chemistry chemical physics : PCCP.

[58]  I. Ercan,et al.  High-grade and low-grade gliomas: differentiation by using perfusion MR imaging. , 2005, Clinical radiology.

[59]  Jonathan P. Dyke,et al.  Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T , 2006, Molecular Cancer Therapeutics.

[60]  M. Essig,et al.  Tumor angiogenesis of low-grade astrocytomas measured by dynamic susceptibility contrast-enhanced MRI (DSC-MRI) is predictive of local tumor control after radiation therapy. , 2001, International journal of radiation oncology, biology, physics.

[61]  Andrea Sbarbati,et al.  Early Antiangiogenic Activity of SU11248 Evaluated In vivo by Dynamic Contrast-Enhanced Magnetic Resonance Imaging in an Experimental Model of Colon Carcinoma , 2005, Clinical Cancer Research.

[62]  W. T. Dixon Simple proton spectroscopic imaging. , 1984, Radiology.

[63]  J. Gore,et al.  Intravascular susceptibility contrast mechanisms in tissues , 1994, Magnetic resonance in medicine.

[64]  R. Kauppinen,et al.  Quantitative 1H nuclear magnetic resonance diffusion spectroscopy of BT4C rat glioma during thymidine kinase-mediated gene therapy in vivo: identification of apoptotic response. , 1998, Cancer research.

[65]  J. Tsuruda,et al.  Diffusion‐weighted MR imaging of extraaxial tumors , 1991, Magnetic resonance in medicine.

[66]  J C Gore,et al.  Studies of restricted diffusion in heterogeneous media containing variations in susceptibility , 1991, Magnetic resonance in medicine.

[67]  William E Grizzle,et al.  Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody. , 2008, Radiology.

[68]  M. Brauer In vivo monitoring of apoptosis , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[69]  Jeff W M Bulte,et al.  In Vivo Magnetic Resonance Tracking of Magnetically Labeled Cells after Transplantation , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[70]  A. Sherry,et al.  Imaging the tissue distribution of glucose in livers using a PARACEST sensor , 2008, Magnetic resonance in medicine.

[71]  Susan M. Chang,et al.  Dynamic susceptibility contrast perfusion imaging of radiation effects in normal‐appearing brain tissue: Changes in the first‐pass and recirculation phases , 2005, Journal of magnetic resonance imaging : JMRI.

[72]  A. Anderson,et al.  Effects of osmotically driven cell volume changes on diffusion‐weighted imaging of the rat optic nerve , 1996, Magnetic resonance in medicine.

[73]  J S Taylor,et al.  Chemical shift imaging of human brain: axial, sagittal, and coronal P-31 metabolite images. , 1990, Radiology.

[74]  Jan Henrik Ardenkjaer-Larsen,et al.  Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis. , 2006, Cancer research.

[75]  Albert P. Chen,et al.  Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. , 2008, Cancer research.

[76]  D. Beyersdorff,et al.  Simultaneous Quantification of Perfusion and Permeability in the Prostate Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging with an Inversion-Prepared Dual-Contrast Sequence , 2009, Annals of Biomedical Engineering.

[77]  T. Seierstad,et al.  Noninvasive monitoring of radiation-induced treatment response using proton magnetic resonance spectroscopy and diffusion-weighted magnetic resonance imaging in a colorectal tumor model. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[78]  M. Décorps,et al.  Vessel size imaging , 2001, Magnetic resonance in medicine.

[79]  N. Hylton,et al.  Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor‐receptor tyrosine kinase inhibitor: Assessment by voxel analysis of dynamic contrast‐enhanced MRI , 2005, Journal of magnetic resonance imaging : JMRI.

[80]  B. D. Ward,et al.  Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis. , 2004, AJNR. American journal of neuroradiology.

[81]  J. Gore,et al.  Noninvasive Detection of Matrix Metalloproteinase Activity In Vivo using a Novel Magnetic Resonance Imaging Contrast Agent with a Solubility Switch , 2007, Molecular imaging.

[82]  Olav Haraldseth,et al.  Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging , 2000, Magnetic resonance in medicine.

[83]  Pernille R. Jensen,et al.  Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate , 2008, Nature.

[84]  J S Petersson,et al.  Molecular imaging using hyperpolarized 13C. , 2003, The British journal of radiology.

[85]  P. Mildenberger,et al.  Assessment of tumor microcirculation with dynamic contrast‐enhanced MRI in patients with esophageal cancer: Initial experience , 2008, Journal of magnetic resonance imaging : JMRI.

[86]  Belinda Seto,et al.  Guest editorialMolecular Imaging1 , 2005 .

[87]  A P Pathak,et al.  Utility of simultaneously acquired gradient‐echo and spin‐echo cerebral blood volume and morphology maps in brain tumor patients , 2000, Magnetic resonance in medicine.

[88]  A. Krishnan,et al.  Detection of cell death in tumors by using MR imaging and a gadolinium-based targeted contrast agent. , 2008, Radiology.

[89]  E E de Lange,et al.  MR imaging and spectroscopy using hyperpolarized 129Xe gas: Preliminary human results , 1997, Magnetic resonance in medicine.

[90]  Scott E. Fraser,et al.  In vivo visualization of gene expression using magnetic resonance imaging , 2000, Nature Biotechnology.

[91]  E F Halpern,et al.  Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. , 1994, Radiology.

[92]  Thomas E Yankeelov,et al.  Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. , 2007, Magnetic resonance imaging.

[93]  A Dean Sherry,et al.  Chemical exchange saturation transfer contrast agents for magnetic resonance imaging. , 2008, Annual review of biomedical engineering.

[94]  E. Rofstad,et al.  Assessment of hypoxia in human cervical carcinoma xenografts by dynamic contrast-enhanced magnetic resonance imaging. , 2009, International journal of radiation oncology, biology, physics.

[95]  Esin Ozturk-Isik,et al.  3D 1H MRSI of brain tumors at 3.0 tesla using an eight‐channel phased‐array head coil , 2007, Journal of magnetic resonance imaging : JMRI.

[96]  R D Tien,et al.  MR imaging of high-grade cerebral gliomas: value of diffusion-weighted echoplanar pulse sequences. , 1994, AJR. American journal of roentgenology.

[97]  Gregory Karczmar,et al.  Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.